NTLA
Intellia Therapeutics, Inc.
Nasdaq In Vitro & In Vivo Diagnostic Substances Large accelerated filer

Key Financials

Net Income
$-412694000
↑ 20.5%
Revenue
$67.7M
↑ 16.9%
Operating Income
$-440990000
↑ 17.5%
Total Assets
$842.1M
↓ 29.3%
EPS (Diluted)
$-3.81
↑ 27.4%
Shareholders' Equity
$671.4M
↓ 23.0%
Cash & Equivalents
$155.5M
↓ 17.8%
Total Liabilities
$170.7M
↓ 46.5%

Recent SEC Filings

Form Type Filed Date Link
8-K 6/15/2026 View on SEC
4 6/10/2026 View on SEC
4 6/10/2026 View on SEC
4 6/10/2026 View on SEC
4 6/10/2026 View on SEC
4 6/10/2026 View on SEC
4 6/10/2026 View on SEC
4 6/10/2026 View on SEC
8-K 6/10/2026 View on SEC
10-Q 5/11/2026 View on SEC

Company Information

Field Value
Ticker NTLA
Company Name Intellia Therapeutics, Inc.
CIK 1652130
Sector In Vitro & In Vivo Diagnostic Substances
Industry Large accelerated filer
Exchange Nasdaq
SIC Code 2835
SIC Description In Vitro & In Vivo Diagnostic Substances
Entity Type operating
Fiscal Year End 1231
State of Incorporation DE
Phone 857-285-6200